Relationship between Differential Hepatic microRNA Expression and Decreased Hepatic Cytochrome P450 3A Activity in Cirrhosis by Raj Vuppalanchi (458660)

“…Notably, miR-155, a known regulator of liver inflammation, had the highest fold increase in cirrhotic livers (2.2-fold, P=4.16E-08) and significantly correlated with hepatic CYP3A activity (r=-0.50, P=0.017). …”

Decrease in activity of transcriptional factor NRF2 in MCF-7 cells exposed to gDNA^OX at final concentrations of 50 ng/mL for 2 hours. by Svetlana V. Kostyuk (473354)

Expression of Egln3 decreases tumor aggression, increases survival and normalizes glioma vascular architecture. by Vicki A. Sciorra (312082)

Reduced RabGEF1 expression decreases NGF-induced TrkA phosphorylation but not TrkA internalization. by See-Ying Tam (828866)

Effects of bFGF on decrease of HG-induced accumulation of intracellular ROS levels. by Yuan Hu Xuan (632639)

Intrathecal injection of mycolactone triggers a decrease of pro-inflammatory cytokines in spinal cord of Sham rats. by Caroline Isaac (4600654)

IC₅₀s data of antimalarials against controls. by Winnie Okore (14139712)

Subjects:

miR-181b overexpression decreases cell mitochondrial membrane potential. by Samira Ghorbani (3843895)

Thimerosal decreases the expression of survivin via the PI3K/Akt pathway. by Wen-Xue Li (189757)

The ratio of standard deviation to mean dose (SD/mean) decreases with neuronal dose. by Murat Alp (781371)

Expression of ApoB-50 decreased lipid accumulation and inhibited HCV production. by Bei Wang (116772)

Drugs IC₅₀s data during the study period. by Winnie Okore (14139712)

Subjects:

Mean and standard deviation values for the Impulse during the first 50 ms of stance (Imp50) during running shod (SH) and barefoot (BF), in both PRE and POST training, where (<sup>a... by Ana Paula da Silva Azevedo (3373688)

Distribution of miRs with a greater than two fold-change. by Stephanie L. Samani (17896610)

Subjects:

Fold change with steady state myocardial mRNA levels for components of the inflammasome. by Stephanie L. Samani (17896610)

Subjects:

Pretreatment of β-cells with recombinant CXCL12 improves viability and induces a decrease in PARP-1 activity. by Nevena Grdović (394542)

VPS34 inhibition decreases intracellular levels of cholesteryl-esters, blocks cholesterol uptake and enhances lysosomal degradation of LDLR. by Marek J. Kobylarz (9292599)

LPLI decreases IκBα degradation and NFκB activation. by Jyun-Yi Wu (103136)

Bay 61–3606 sensitizes MCF-7 cells to TRAIL by decreasing Mcl-1. by So-Young Kim (562174)

SNPs IC₅₀s data at codon 876 during the study period. by Winnie Okore (14139712)

Subjects: